Cancer Elderly Fatigue Insomnia Pain Symptoms Pain (P), fatigue (F), and insomnia (I) are among the most prevalent, distressing, and undermanaged symptoms experienced by cancer patients. Research has demonstrated that PFI co-occur; what remain unclear are the patterns and stability of PFI and the patient, disease, and treatment characteristics that predict PFI patterns over time. This secondary analysis used a data set composed of 867 elders (46% women) who were newly diagnosed with breast, colorectal, lung, or prostate cancer and followed at 4 points during the year after diagnosis. The university's institutional review board approved this study. Descriptive statistics and multistate transition models using multinomial logistic regression were used. The typical participant was 72.6 years old, who reported 7.9 symptoms and 2.7 comorbidities.
Participants
The target population for the parent study included persons 65 years or older who were newly diagnosed with breast, colorectal, lung, or prostate cancer. The rationale for limiting the cancer site to breast, colorectal, lung, or prostate was that these are the 4 most frequently occurring types of cancer among persons in this age stratum. Using convenience sampling, participants were accrued from 24 communities in the Lower Peninsula of Michigan, excluding the Detroit Metropolitan area, and from one community in Indiana. Within these 24 communities, active recruitment occurred in 30 different treatment settings, including hospitals, oncology physician offices, and community cancer treatment centers.
Elders were eligible to participate if they were 65 years or older; were newly diagnosed with breast, colorectal, prostate, or lung cancer; were currently undergoing some form of treatment beyond palliation; could speak and read the English language; did not receive treatment in the previous 3 years for another cancer; and had a telephone. Patients were ineligible for participation in the study if they had hearing or cognitive deficits such as dementia or did not have a telephone. Inclusion criteria for these secondary analyses included participant sex, age, cancer site, and stage of disease documented in the data set. The parent study was a patientcaregiver dyad study, in which the patient identified a primary caregiver who would assist with care in the home setting, and the patients were not caregivers to an ill, elderly spouse. Identified caregivers were interviewed separately from the patient; the caregiver data are not presented in this article. The parent study enrolled 1,200 elder cancer patients. Nine hundred seventy-six persons (81.33% of the parent study sample) met the eligibility criteria for this secondary analysis. One hundred nine participants who consented did not provide data at any data collection period. Of these 109 persons who consented to participate but did not provide any data, 34 (31%) were too ill, 12 (11%) could not be reached, 47 (43%) changed their mind and refused the study upon initial telephone contact, 11 (10%) had hearing deficits that precluded participation in a telephone interview, 4 (4%) wished to have only their caregiver participate in the study, and 1 (1%) died after giving consent but before the first (wave 1) interview.
Procedures
After giving their informed consent, elders participated in telephone interviews at 4 points in time: 6 to 8 weeks (wave 1), 12 to 16 weeks (wave 2), 24 weeks (wave 3), and 52 weeks (wave 4) after cancer diagnosis. Timing for the first and second interviews was linked to timing of receipt of radiation therapy or chemotherapy; timing for the last 2 interviews captured immediate posttreatment effects and sustained/ decay effects secondary to disease and treatment. Retrospective medical record audits were conducted to verify site and stage of cancer, surgical procedures performed, and treatments received.
Measures

SOCIODEMOGRAPHIC QUESTIONNAIRE
This 10-item instrument asked participants to disclose social and demographic information, including but not limited to sex, date of birth, educational background, and marital status. Responses to all questions were close ended and came from either a listed response set or a specific number or date provided by the participant. The principal investigators from the parent study developed the sociodemographic questionnaire.
COMORBIDITY INDEX
This 15-item instrument is a self-report measure of preexisting and coexisting comorbid conditions with which the participant had been given a diagnosis by a healthcare professional. Response categories to these questions were both close ended, with yes/no/do not know/refused or Likert scale options, and, as in the case of the final question, open ended, with the participant having the opportunity to report any health condition(s) that had not been identified through the instrument. This instrument is a condensed version of the larger Aging and Health in America instrument that was developed by the Survey Research Center of the University of Michigan 26 for use in geriatric populations. The Aging and Health in America questionnaire was developed using a weighted sample of more than 9,000 older Americans of varied ethnicity and is a valid instrument for capturing selfreported health conditions in older Americans. Preexisting comorbidity was captured through self-report; as previous research by Katz and colleagues 27 demonstrated, an overall level of agreement between the medical recordYbased audit and their questionnaire exceeded 90%. Because only 7% (n = 65) of our sample reported no preexisting health conditions, comorbidity was dichotomized into 0 to 3 or 4 or more comorbid conditions for the purposes of modeling.
PATIENT SYMPTOM EXPERIENCE
This 37-item instrument is a self-report measure that asked participants if they had experienced any of the 37 listed symptoms during the previous 2 weeks because of their cancer or cancer treatment. If participants answered affirma-tively to any symptom, they were asked to rate the symptom's severity on a 3-point scale: mild, moderate, or severe. Participants were then asked to rate on a 5-point scale the extent to which the symptom disrupted or caused them to limit their regular daily activities: no extent, small extent, some extent, great extent, or very great extent. This instrument was developed by Given and Given, in lieu of Kurtz and colleagues, 28 was based on other symptom inventories used in cancer populations, such as the Symptom Distress Scale, 29 and is a valid instrument for capturing symptom severity. The Cronbach ! coefficient for this instrument was .90. 30 
Data Analysis
Descriptive statistics were run to describe the subsample's characteristics specific to sex, race, cancer site, cancer stage, comorbid conditions, educational level, marital status, and living situation.
Our primary research question was ''Do patient sex, age, comorbidity status, cancer site, stage of disease, or treatment regimen predict patterns of PFI over time?'' To address this, we fit multistate transition models using multinomial logistic regression. Multinomial logistic regression is used in circumstances in which the dependent variable is categorical and the categories do not have any particular rank order; there is no restriction on the level of measurement of the predictor/ independent variables. 31 Based on symptom prevalence patterns, we defined mutually exclusive and exhaustive symptom categories as (1) no PFI symptoms; (2) F only; (3) P, I, or both without F; (4) F with another symptom; and (5) all 3 symptoms.
Multinomial logistic regression describes ratios of the risks of falling into each outcome category versus a reference category, comparing a particular regressor value versus a reference category (nominal regressors) or a contrast of one unit (continuous regressors). In our models, each PFI outcome category was compared with the ''no PFI symptoms'' (reference) category. Each category has its own unique linear prediction model, including intercept, ! value, and vector of coefficients, so that there is a distinct coefficient " ik that corresponds to every regressor and category. Multinomial logistic regression assumes linear relationships between the independent variables and the log ratios of outcome category prevalences.
At the first observation time, the selected variables for predicting symptom pattern prevalences were sex, age, comorbidity category, treatment category, surgery status, cancer site, and stage of disease. At the subsequent observation times, these variables, as well as the previous state PFI pattern that each elder reported, were considered as current symptom pattern prevalence predictors. Diagnostics via the variance inflation factor (VIF) method were conducted at each observation time to determine whether the first-order predictor variables were highly correlated. A conservative rule for this determination is that no individual VIF score be greater than 10 and that the mean of all the VIFs is not considerably larger than 1. 32 The mean VIF scores at each data collection point ranged from 1.76 to 1.83; at each observation time, none of the individual VIF scores exceeded 4.46.
Model building was conducted using likelihood ratio tests for hierarchically nested models and introduced a number of interaction terms to explore whether (1) comorbidity category (0Y3 vs = 4 comorbid conditions) interacted with cancer site, cancer stage, or treatment and (2) cancer site interacted with stage of disease or sex to predict PFI patterns at the 6-week data collection period. At subsequent observation times, the interaction of previous PFI state with comorbidity category was also tested. Analyses were conducted using STATA 33 SE version 9. There were instances in which there were few (or no) individuals with combinations of covariates within outcome categories. With sparse cell sizes, interactions of interest could not be estimated and, in some cases, not even the main effects; not applicable (NA) denotes such cases.
n Results
Sample Characteristics
Eight hundred sixty-seven persons met the eligibility criteria and provided data for this secondary analysis. The typical participant was slightly older than 72 years, was white, reported more than 2 preexisting comorbid conditions, was married and living with his/her spouse, and had attained a high school diploma or higher level of education. In this subset, 54% (n = 465) were men and 46% (n = 402) were women. The cancer composition of this subset included prostate (n = 285, 29%), breast (n = 234, 27%), lung (n = 221, 24%), and colorectal (n = 153, 18%) cancer; 593 (68%) were diagnosed with early-stage disease, and 274 (32%) were diagnosed with late-stage disease. Table 1 provides the sociodemographic data for the elders.
The top 5 most frequently reported comorbid conditions included (1) hypertension (50.3%, n = 406), (2) heart problems (31%, n = 250), (3) hearing deficit (24.9%, n = 201), (4) vision deficit (23.2%, n = 187), and (5) arthritis (20.5%, n = 166).
At the wave 1 observation period, 846 (98%) elders completed the interviews; subsequently, the numbers were 723 (83%) at the wave 2 observation period, 664 (77%) at the wave 3 observation period, and 592 (68%) at the wave 4 observation period. Five hundred eighteen (60%) elders completed all 4 interviews. Statistical tests were conducted to explore whether sociodemographic or physical characteristics of the study sample were associated with completing versus not completing the 4 waves of data collection. Completing all 4 interviews was associated with being female (# 1 2 = 9.857, P = .002); being diagnosed with breast, colorectal, or prostate cancer in comparison with lung cancer (# 3 2 = 88.133, P = .000); having early-stage disease (# 1 2 = 72.099, P = .000); being younger (F = 4.313, P = .038); being white (# 3 2 = 8.566, P = .036); and having a high school diploma or higher level of education (# 6 2 = 42.429, P = .000). There was no association between completing all 4 waves of data collection and comorbidity category (# 1 2 = 1.055, P = .304), marital status (# 3 2 = 1.296, P = .730), or living situation (# 2 2 = 0.822, P = .663).
The study participants received a variety of treatments for their cancers, including surgical excision of the tumor (n = 667, 68%) and/or chemotherapy alone (n = 93, 9.5%), radiation therapy alone (n = 328, 33.6%), or chemotherapy with radiation therapy (n = 129, 13.2%). There was no association between completing all 4 waves of data collection and treatment category (no adjuvant therapy, chemotherapy alone, radiation therapy alone, or chemotherapy plus radiation therapy) (# 3 2 = 4.027, P = .260). There was an association between having surgery and completing all 4 waves of data collection (# 1 2 = 71.789, P = .000); however, most study participants underwent surgery and completed all 4 waves of data collection. Symptom Prevalence Shifts and Interrelationships Over Time Pain, fatigue, and insomnia pattern prevalences shifted over time after cancer diagnosis. The prevalence of PFI cooccurrence peaked at wave 1 (6Y8 weeks after cancer diagnosis), with 18% (n = 152) of the elders reporting PFI co-occurrence (see Table 2 ). At each subsequent wave of data collection, PFI co-occurrence steadily decreased such that by wave 4 (1 year after diagnosis), 6% (n = 35) of the elders reported PFI co-occurrence. Conversely, reports of no PFI were at their lowest at wave 1, with 18% (n = 155) of the elders reporting no PFI. Over time, an inverse trend was noted between PFI co-occurrence and no PFI; by wave 4, no PFI was reported by 43% (n = 256) of the elders, although 336 (57%) reported at least one of these symptoms. Pain, fatigue, and insomnia did not have high intercorrelations for any wave of data collection. Wave 1 correlations for PFI included PI (r = 0.20), FI (r = 0.15), and FP (r = 0.20). Pain, fatigue, and insomnia correlations for subsequent waves were very similar. These intercorrelations were higher than those found by Dodd and colleagues 15 but lower than those reported by Beck and colleagues. 17 
PFI Predictors at Wave 1
The final model for predicting PFI patterns at the wave 1 observation period included patient sex, comorbidity status, cancer site, stage of disease, treatment modality, surgery, and comorbidity Â cancer site interaction. Likelihood ratio testing indicated that the interaction terms comorbidity Â treatment, comorbidity Â stage, cancer site Â stage, and cancer site Â sex were not significant; thus, they were not included in the final model. Age was not associated with significant risks of any of the PFI patterns (likelihood ratio, # 4 2 = 5.54, P = .236) and was not included in the final model. Table 3 displays the relative risk ratios (RRRs) and 95% confidence intervals (CIs) for each predictor variable, by PFI pattern, for the wave 1 observation period.
PFI Predictors at Wave 2
The final model for predicting the wave 2 PFI patterns included patient sex, comorbidity status (0Y3 vs =4 comorbid conditions), cancer site, stage of disease, treatment modality, previous PFI state, and the cancer site Â stage interaction. Likelihood ratio testing indicated that comorbidity Â treatment, comorbidity Â cancer site, comorbidity Â stage, comorbidity Â previous PFI state, and cancer site Â sex were not significant predictors; thus, they were not included in the final model. In addition, age was excluded from the final model because it was not associated with significant risks of any of the PFI patterns (likelihood ratio, # 4 2 = 5.37, P = .252). Table 4 displays the RRRs and 95% CIs of the predictor variables (see Table 3 ). Noteworthy in Table 4 are the NAs in the outcome categories (a) FI or FP and (b) PFI co-occurrence for the interaction term stage Â breast cancer. These statistics owe to the result that none of the late-stage breast cancer patients reported either of the outcomes at issue at wave 2.
PFI Predictors at Wave 3
The final model for predicting the wave 3 PFI patterns included patient sex, comorbidity status (0Y3 vs =4 comorbid conditions), cancer site, stage of disease, treatment modality, and previous PFI state. Likelihood ratio testing indicated that comorbidity Â treatment, comorbidity Â cancer site, comorbidity Â stage, comorbidity Â previous PFI state, cancer site Â stage, and cancer site Â sex were not significant predictors; thus, they were not included in the final model. As for waves 1 and 2, age was also excluded; it was not associated with significant risks of any of the PFI patterns (likelihood ratio, # 4 2 = 8.13, P = .087). Table 5 displays the RRRs and 95% CIs of the predictor variables.
PFI Predictors at Wave 4
The initial model for predicting the wave 4 PFI patterns included patient sex, comorbidity status (0Y3 vs = 4 comorbid conditions), cancer site, stage of disease, treatment, surgery, and previous PFI state and the comorbidity Â previous PFI state, cancer site Â stage, and cancer site Â sex interactions. Age was not associated with significantly increased risk of any of the PFI patterns at wave 4 and was thus omitted (likelihood ratio, # 4 2 = 2.70, P = .61). It was noted that the comorbidity Â previous PFI state interaction terms were associated with clinically meaningless RRRs for wave 4 PFI patterns, and many of the 95% CIs for these comorbidity Â previous PFI pattern interaction terms were undefined. For example, in the outcome category FI or FP, the association between higher comorbidity and reporting FI or FP at wave 4 was reduced by 93% in the presence of fatigue at wave 3. Although this is a statistically significant finding, we suspected it to be an artifact of model overfit because of cell sizes for comorbidity Â previous PFI state Â PFI pattern at wave 4. In fact, a cross-tabulation of wave 4 PFI patterns Â comorbidity Â previous PFI state at wave 3 included 3 cells that contained a zero value. The decision was made to omit the comorbidity Â previous PFI state interaction terms from the final wave 4 model. In addition, Table 6 provides a display of the RRRs and 95% CIs for each of the predictor variables.
Finally, we also considered other symptoms that may have contributed to PFI patterns but were not included in the primary analyses. Table 7 displays the mean number of other symptoms that patients reported, by PFI pattern and by wave of data collection. Participants who did not report PFI at any wave reported, on average, 3 other symptoms. As participants reported various PFI patterns, the mean number of other symptoms reported ranged from 4 to more than 9 (across all PFI patterns, across all waves of data collection). Thus, elder cancer patients who experience pain, fatigue, and/or insomnia throughout their cancer and treatment trajectories may be susceptible to experiencing many other symptoms.
Attrition and Its Predictors Over Time
Two hundred fifty-five (29%) cases provided data for only the wave 1 observation. In an effort to understand how PFI patterns and other variables of interest predicted attrition at the subsequent observations, post hoc analyses were con-ducted. Eighty-eight of the elders who met eligibility criteria for this secondary analysis died while participating in the parent study; one of the elders died after giving consent but before participating in the first data collection. In addition, 167 elders were lost to follow-up (LTF) but did not die after completion of the wave 1 data collection. At the wave 2 observation, 15 elders had died and 108 elders were LTF. Significant predictors for death at wave 2 included having a diagnosis of colorectal or lung cancer, having late-stage disease, receiving chemotherapy, and reporting PFI at wave 1. Significant predictors for being LTF at wave 2 included having a diagnosis of lung cancer, having late-stage disease, receiving chemotherapy or radiation therapy (alone or in combination), and reporting the PFI patterns of FI or FP, or PFI at wave 1. At the wave 3 observation, an additional 38 elders had died and 21 elders were LTF. Significant predictors for death at wave 3 included having a diagnosis of lung cancer, having late-stage disease, and reporting the PFI patterns of FI or FP, or PFI at wave 2. Significant predictors for being LTF at wave 3 included having a diagnosis of lung cancer and reporting the PFI patterns of P, I, or PI, or PFI at wave 2.
At the wave 4 observation, an additional 34 elders had died and 38 elders were LTF. Significant predictors for death at wave 4 included having 4 or more comorbid conditions, having a diagnosis of lung cancer, having late-stage disease, and reporting the PFI patterns of P, I, or PI; FI or FP; or PFI at wave 3. Significant predictors for being LTF at wave 4 included a diagnosis of lung cancer and reporting the PFI patterns FI or FP, or PFI at wave 3.
n Limitations
There are limitations to this study that merit discussion. The parent study used convenience sampling, and although convenience sampling is an efficient and cost-effective means for accruing a study sample, its limitations are acknowledged. Specifically, self-selection into any research endeavor may impose extraneous characteristics that, while not part of the study, may influence the analyses because of the influence of, or relatedness to, the outcome of interest.
Data were not gathered from individuals who met the eligibility for participation but declined to participate. Therefore, comparisons cannot be made on variables of interest, such as patient age, sex, or race; site of cancer or stage of disease; or preexisting comorbidity, to explore possible predictors for nonparticipation. It seems plausible that eligible persons who had many symptoms would decline participation. In addition, participants were excluded from the study if they did not have a telephone, could not hear normal conversation, or did not speak and understand the English language. The extent to which these excluded persons differed from those who fully met the eligibility requirements for participation is unclear because there were no demo-graphic data gathered from those individuals who were excluded, from which comparisons could be made.
Despite the multiple sites used for recruitment, the sample was racially homogeneous, with the sample being composed of white (n = 806, 93%), African American (n = 55, 6%), Latino (n = 2, G1%), and Native American (n = 4, G1%) elders. Because of the lack of racial variability in this sample, it was impossible to make any PFI patterning comparisons by race.
With the exception of data directly related to the participants' cancers (site, stage, and adjuvant therapy), the data for this secondary analysis were obtained through selfreport/participant interviews. Although the work of Katz and colleagues 27 demonstrated a high level of agreement between self-report of comorbidity and medical record audit, we do acknowledge that persons may overreport or underreport health conditions. Whether these elder cancer patients were receiving adjuvant medications such as antianxiety, analgesics, antidepressants, antiemetics, hypnotics, erythropoiesis-stimulating agents, or growth-stimulating factors was not available in the data set. Thus, although we acknowledge that adjuvant medications clearly would affect the participants' symptom experiences, for the purposes of this secondary analysis, we were unable to address the effects of adjuvant medications on our outcomes of interest.
Retention of participants in longitudinal studies is a challenge, and we acknowledge the effects of attrition from the study. We have previously addressed the issue of attrition from this study and the relationships between our outcomes of interest and participant death or loss to follow-up. Attrition from this study imposes a threat to the external validity of this study.
n Discussion
This secondary analysis found that advancing age was not significantly associated with increased risks of patterns of PFI. The Helme and Gibson 34 review on the epidemiology of pain in elders reported that after the seventh decade of life, reports of pain in the elderly decline. This decrease in pain reporting may be attributable to age-related changes in nociceptive functioning, specifically peripheral and central nervous system pathways. 34 Sex was associated with significant risks of reporting FI or FP at the wave 3 observation and reporting fatigue at wave 4, such that being female carried RRRs of 2.5 and 3.21, respectively, for reporting these patterns when compared with being male. Research that explored sex differences in pain, fatigue, and insomnia as isolated symptoms in cancer patients is minimal. Despite this paucity, research has shown no sex differences in reports of average, worst, or least pain intensity scores, 35 and women report greater levels of fatigue and sleep disturbance. 36 Comorbidity was a prevailing issue among this sample of elders, with only 7% (n = 65) reporting no preexisting comorbid conditions. The typical elder reported more than 2 comorbid conditions, and 27% (n = 236) reported 4 or more comorbid conditions. Thirty-one percent of the elders reported being told by a healthcare professional that they had heart problems; 20%, arthritis; 50%, high blood pressure; and just fewer than 16%, chronic lung disease. Having 4 or more comorbid conditions was associated with a 2-fold increased RRR for reporting fatigue at wave 1. Increased comorbidity in the presence of breast cancer was associated with 4-and 7-fold increased RRRs for reporting the pattern FI or FP or the pattern PFI, respectively, at wave 1. It is curious that comorbidity as either a first-order term or an interaction term was not a significant predictor for PFI patterns at wave 2 or 3.
Treatment modality (single and multimodal) was associated with significantly increased risks of PFI patterns at waves 1, 2, and 3, coinciding with the initial phase, midpoint, and completion of adjuvant therapy, respectively. Thus, we were able to observe the immediate and accumulative effects of cancer treatment. Of note, the greatest impact of treatment on predicting PFI patterning was noted at the wave 2 observation. At the wave 4 observation, which was scheduled at 52 weeks after diagnosis, treatment modality was no longer significantly associated with increased risks of reporting PFI patterns. Table 2 highlights the fluid nature of PFI patterns over time, namely, that the participants' reports of PFI co-occurrence lessened over time, with movement toward no reports of PFI. Although of interest, there were some elders who moved from reporting F, P, or I or PI at one observation to reporting FI or FP, or PFI at the subsequent observation. Despite these findings, a moderate proportion of this sample reported problems with ongoing pain (25.2%), fatigue (40.4%), and insomnia (23.2%) 1 year after their cancer diagnosis.
Thirty-percent of the population of elders who consented to participate in the parent study did not complete the study. One hundred nine elders withdrew from the study upon initial contact for the wave 1 interview. Among those elders who were included in this secondary analysis and completed the first wave of data collection, 88 elders died and an additional 167 elders withdrew from the study at subsequent data collections. Having a lung cancer diagnosis, having latestage disease, and reporting PFI at a previous observation were each significantly associated with death at the wave 2, 3, and 4 observations. Being diagnosed with lung cancer and reporting PFI at a previous observation were significantly associated with being LTF at the wave 2, 3, and 4 observations. Because an outcome of interest, PFI co-occurrence, was significantly associated with attrition at waves 2, 3, and 4, our remaining sample for these waves of analysis may have been biased such that variables not shown to be statistically significant predictors of PFI patterns may be predictive of increased RRRs for PFI patterning. In addition, this study did not explore the contribution of other symptoms in predicting either PFI patterns or attrition, yet further analyses demonstrated that elders who reported PFI co-occurrence at any observation also reported, on average, 9 other symptoms.
It is apparent that there exists an association between PFI patterns and the number of other symptoms being reported, but causal direction cannot be asserted through the results from this secondary analysis. What are not yet fully appreciated are the mechanisms through which PFI patterns occur over time. This study explored the patient, disease, and treatment predictors of PFI patterns but was not able to explore how biological/immunologic mechanisms may have impacted PFI patterning. Past work has suggested a relationship between cancer and treatment-related symptoms and proinflammatory cytokines. 15, 37, 38 The bidirectional association between pain (acute or chronic) and sleep disturbance is well articulated. 39, 40 A recent study involving healthy volunteers reported that restricted sleep was significantly associated with increased interleukin-6 levels and subsequent increases in complaint of bodily pain and fatigue/tiredness, 41 providing further evidence that pain, fatigue, and insomnia may have a biological link.
Cancer survivors often seek their posttreatment healthcare needs through primary care providers, who may or may not be familiar with the long-term effects of cancer and/or its treatment. An additional issue that must be addressed is that of advancing age and the degree to which cancer and treatment-related symptoms in the elderly may not be sufficiently managed. We must question whether this insufficient management stems from a belief that cancer and treatment-related symptoms are a normative experience in the elderly. Again, the results of this study do not elucidate why these elders had unmanaged or undermanaged symptoms throughout the study, only that they reported symptoms throughout the first year after their cancer diagnosis.
n Research Implications
Despite what this study demonstrated regarding the patterning of pain, fatigue, and insomnia, there are numerous gaps in the state of our knowledge of these 3 cardinal symptoms in cancer. Additional research is needed to explore (1) whether there are sex differences in pain, fatigue, and insomnia patterning; (2) whether there are moderating effects among pain, fatigue, and insomnia, such that in the presence of any 2 or all 3 of these symptoms, a synergistic effect occurs to attract other symptoms; (3) whether a biological or immunologic link exists among pain, fatigue, and insomnia; (4) the time-ordered nature of pain, fatigue, and insomnia presentation in cancer patients, specifically, does one symptom ''drive'' the appearance of the others; (5) how preexisting pain, fatigue, and insomnia may impact disease progression and response to cancer treatment; and (6) the impact of intervening on pain, fatigue, and insomnia on other symptom reports.
n Practice Implications Symptom management is an issue and priority in all oncology settings, regardless of the patient's age, site of cancer, or treatment protocol. Nursing is in a pivotal role to facilitate symptom management for elderly cancer patients through (1) ongoing assessment for cancer and treatment-related symptoms, including severity and impacts on usual daily activities and functional ability, and (2) ongoing assessment of the effectiveness of symptom management strategies implemented by the elder cancer patients or their family caregiver. In the event that the symptom management strategies used have been ineffective, the nurse can suggest alternative symptom management strategies and should provide parameters to the elder cancer patients and their family caregivers for involving the healthcare system (nurses and physicians). In the event that family caregivers are not involved in symptom management, the nurse should assess the willingness of the family caregiver to provide assistance when it is needed, as well as the willingness of the elder cancer patient to ask for assistance when it is needed and accept assistance when and if it is offered.
n Summary Cancer and treatment-related symptoms rarely occur in isolation. Among the many symptoms that a person diagnosed with cancer may experience, pain, fatigue, and insomnia are perhaps the most prevalent and problematic cancer and treatment-related symptoms. Pain, fatigue, and insomnia may be particularly problematic among elder cancer patients; preexisting comorbidity and/or age-related changes in sleep architecture and continuity may predispose elder cancer patients to increased risks of PFI patterns throughout the cancer and treatment trajectories, as well as into the posttreatment phase. This study provided evidence that previous PFI patterns were significantly associated with increased RRRs for ongoing PFI and even death, and PFI patterns were associated with increased reports of other symptoms. A moderate proportion of our elders continued to experience PFI patterns up to 1 year after their cancer diagnosis. Thus, interventions targeted toward the amelioration of pain, fatigue, and insomnia have the potential to reduce the adverse consequences that elders may experience secondary to pain, fatigue, and insomnia and improve quality of life.
